Postmenopausal hormone therapy and the risk of venous thromboembolism

References

• Cushman M, Kuller L H, Prentice R, et al. Estrogen plus progestin and risk of venous thrombosis. JAMA 2004; 292: 1573–1580
   PubMed Web of Science ®Google Scholar
• Wu O. Postmenopausal hormone replacement therapy and venous thromboembolism. Gender Med 2005; 2(Suppl A)S18–S27
   PubMedGoogle Scholar
• Web page address: http://www.nhlbi.nih.gov/whi. Accessed on 7th December, 2007
   Google Scholar
• Curb J D, Prentice R L, Bray P F, et al. Venous thrombosis and conjugated equine estrogen in women without a uterus. Arch Intern Med 2006; 166: 772–780
   PubMed Web of Science ®Google Scholar
• Rossouw J E, Anderson G L, Prentice R L, et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA 2002; 288: 321–333
   PubMed Web of Science ®Google Scholar
• Rachon D, Zdrojewski T, Suchecka-Rachon K, et al. Knowledge and use of hormone replacement therapy among Polish women: estimates from a nationally representative study – HORTPOL 2002. Maturitas 2004; 47: 31–37
   PubMed Web of Science ®Google Scholar
• Ringa V, Ledesert B, Gueguen R, Schiele F, Breart G. Determinants of hormonal replacement therapy in recently postmenopausal women. Eur J Obstet Gynecol Reprod Biol 1992; 45: 193–200
   PubMed Web of Science ®Google Scholar
• Teede H J, McGrath B P, Turner A, Majewski H. Effects of oral combined hormone replacement therapy on platelet aggregation in postmenopausal women. Clin Sci (Lond) 2001; 100: 207–213
   PubMed Web of Science ®Google Scholar
• Peverill R E, Teede H J, Smolich J J, et al. Effects of combined oral hormone replacement therapy on tissue factor pathway inhibitor and factor VII. Clin Sci (Lond) 2001; 101: 93–99
   PubMed Web of Science ®Google Scholar
• Scarabin P Y, Alhenc-Gelas M, Plu-Bureau G, Taisne P, Agher R, Aiach M. Effects of oral and transdermal estrogen/progesterone regimens on blood coagulation and fibrinolysis in postmenopausal women. A randomized controlled trial. Arterioscler Thromb Vasc Biol 1997; 17: 3071–3078
   PubMed Web of Science ®Google Scholar
• Vehkavaara S, Silveira A, Hakala-Ala-Pietila T, et al. Effects of oral and transdermal estrogen replacement therapy on markers of coagulation, fibrinolysis, inflammation and serum lipids and lipoproteins in postmenopausal women. Thromb Haemost 2001; 85: 619–625
   PubMed Web of Science ®Google Scholar
• Teede H J, McGrath B P, Smolich J J, et al. Postmenopausal hormone replacement therapy increases coagulation activity and fibrinolysis. Arterioscler Thromb Vasc Biol 2000; 20: 1404–1409
   PubMed Web of Science ®Google Scholar
• Hoibraaten E, Qvigstad E, Arnesen H, Larsen S, Wickstrom E, Sandset P M. Increased risk of recurrent venous thromboembolism during hormone replacement therapy – results of the randomized, double-blind, placebo-controlled estrogen in venous thromboembolism trial (EVTET). Thromb Haemost 2000; 84: 961–967
   PubMed Web of Science ®Google Scholar
• Hoibraaten E, Os I, Seljeflot I, Andersen T O, Hofstad A, Sandset P M. The effects of hormone replacement therapy on hemostatic variables in women with angiographically verified coronary artery disease: results from the estrogen in women with atherosclerosis study. Thromb Res 2000; 98: 19–27
   PubMed Web of Science ®Google Scholar
• Cieplluch R, Czestochowska E. Influence of hormone replacement therapy (17 beta-OH estradiol and medroxyprogesterone acetate) on plasma concentration of prothrombin fragment F1 + 2 and thrombin-antithrombin III complex in postmenopausal woman. Acta Haematol Pol 1996; 27: 21–25
   PubMedGoogle Scholar
• Ciepluch R, Czestochowska E. [Activity of endogenous anticoagulants (antithrombin III, protein C and protein S) in women after menopause treated with hormone replacement therapy (transdermal 17 beta-OH estradiol and oral medroxyprogesterone acetate)]. Ginekol Pol 1996; 67: 407–410
   PubMedGoogle Scholar
• Ciepluch R, Czestochowska E. [Activity of plasminogen activator inhibitor (PAI-1) in plasma of women treated after menopause with hormone replacement therapy]. Pol Tyg Lek 1995; 50: 13–15
   PubMedGoogle Scholar
• Oger E, Alhenc-Gelas M, Lacut K, et al. Differential effects of oral and transdermal estrogen/progesterone regimens on sensitivity to activated protein C among postmenopausal women: a randomized trial. Arterioscler Thromb Vasc Biol 2003; 23: 1671–1676
   PubMed Web of Science ®Google Scholar
• Post M S, Christella M, Thomassen L G, et al. Effect of oral and transdermal estrogen replacement therapy on hemostatic variables associated with venous thrombosis: a randomized, placebo-controlled study in postmenopausal women. Arterioscler Thromb Vasc Biol 2003; 23: 1116–1121
   PubMed Web of Science ®Google Scholar
• Rachon D, Suchecka-Rachon K, Hak L, Mysliwska J. Effects of intranasal 17beta-estradiol administration on serum bioactive interleukin-6 and C-reactive protein levels in healthy postmenopausal women. Menopause 2006; 13: 840–845
   PubMed Web of Science ®Google Scholar
• Lowe G D, Upton M N, Rumley A, McConnachie A, O'Reilly D S, Watt G C. Different effects of oral and transdermal hormone replacement therapies on factor IX, APC resistance, t-PA, PAI and C-reactive protein – a cross-sectional population survey. Thromb Haemost 2001; 86: 550–556
   PubMed Web of Science ®Google Scholar
• Cano A, Van Baal W M. The mechanisms of thrombotic risk induced by hormone replacement therapy. Maturitas 2001; 40: 17–38
   PubMed Web of Science ®Google Scholar
• Perrot-Applanat M, Cohen-Solal K, Milgrom E, Finet M. Progesterone receptor expression in human saphenous veins. Circulation 1995; 92: 2975–2983
   PubMed Web of Science ®Google Scholar
• Canonico M, Oger E, Plu-Bureau G, et al. Hormone therapy and venous thromboembolism among postmenopausal women: impact of the route of estrogen administration and progestogens: the ESTHER study. Circulation 2007; 115: 840–845
   PubMed Web of Science ®Google Scholar
• Herkert O, Kuhl H, Sandow J, Busse R, Schini-Kerth V B. Sex steroids used in hormonal treatment increase vascular procoagulant activity by inducing thrombin receptor (PAR-1) expression: role of the glucocorticoid receptor. Circulation 2001; 104: 2826–2831
   PubMed Web of Science ®Google Scholar
• Tsai A W, Cushman M, Rosamond W D, Heckbert S R, Polak J F, Folsom A R. Cardiovascular risk factors and venous thromboembolism incidence: the longitudinal investigation of thromboembolism etiology. Arch Intern Med 2002; 162: 1182–1189
   PubMed Web of Science ®Google Scholar
• Abdollahi M, Cushman M, Rosendaal F R. Obesity: risk of venous thrombosis and the interaction with coagulation factor levels and oral contraceptive use. Thromb Haemost 2003; 89: 493–498
   PubMed Web of Science ®Google Scholar
• Herrington D M, Vittinghoff E, Howard T D, et al. Factor V Leiden, hormone replacement therapy, and risk of venous thromboembolic events in women with coronary disease. Arterioscler Thromb Vasc Biol 2002; 22: 1012–1017
   PubMed Web of Science ®Google Scholar
• Rosendaal F R, Vessey M, Rumley A, et al. Hormonal replacement therapy, prothrombotic mutations and the risk of venous thrombosis. Br J Haematol 2002; 116: 851–854
   PubMed Web of Science ®Google Scholar
• Wu O, Greer I A. Is screening for thrombophilia cost-effective?. Curr Opin Hematol 2007; 14: 500–503
   PubMed Web of Science ®Google Scholar
• Straczek C, Oger E, Yon de Jonage-Canonico M B, et al. Prothrombotic mutations, hormone therapy, and venous thromboembolism among postmenopausal women: impact of the route of estrogen administration. Circulation 2005; 112: 3495–3500
   PubMed Web of Science ®Google Scholar
• Prandoni P, Lensing A W, Cogo A, et al. The long-term clinical course of acute deep venous thrombosis. Ann Intern Med 1996; 125: 1–7
   PubMed Web of Science ®Google Scholar
• Goldhaber S Z, Grodstein F, Stampfer M J, et al. A prospective study of risk factors for pulmonary embolism in women. JAMA 1997; 277: 642–645
   PubMed Web of Science ®Google Scholar
• Risk of and prophylaxis for venous thromboembolism in hospital patients. Thromboembolic Risk Factors (THRIFT) Consensus Group. BMJ 1992; 305: 567–574
   PubMed Web of Science ®Google Scholar
• Grady D, Hulley S B, Furberg C. Venous thromboembolic events associated with hormone replacement therapy. JAMA 1997; 278: 477
   PubMed Web of Science ®Google Scholar
• Grady D, Wenger N K, Herrington D, et al. Postmenopausal hormone therapy increases risk for venous thromboembolic disease. The Heart and Estrogen/progestin Replacement Study. Ann Intern Med 2000; 132: 689–696
   PubMed Web of Science ®Google Scholar
• Mosca L, Collins P, Herrington D M, et al. Hormone replacement therapy and cardiovascular disease: a statement for healthcare professionals from the American Heart Association. Circulation 2001; 104: 499–503
   PubMed Web of Science ®Google Scholar
• van der Vies J. Pharmacological studies with (7 alpha,17 alpha)- 17-hydroxy-7-methyl-19-norpregn-5(10)-en-20-yn-3-one (Org OD 14). Maturitas 1987; Suppl 1: 15–24
   PubMedGoogle Scholar
• Winkler U H, Altkemper R, Kwee B, Helmond F A, Coelingh Bennink H J. Effects of tibolone and continuous combined hormone replacement therapy on parameters in the clotting cascade: a multicenter, double-blind, randomized study. Fertil Steril 2000; 74: 10–19
   PubMed Web of Science ®Google Scholar
• Cummings S R, Eckert S, Krueger K A, et al. The effect of raloxifene on risk of breast cancer in postmenopausal women: results from the MORE randomized trial. Multiple Outcomes of Raloxifene Evaluation. JAMA 1999; 281: 2189–2197
   PubMed Web of Science ®Google Scholar